-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2695 Monoclonal Gammopathy of Ocular Significance (MGOS) – a Series of Corneal Manifestations and Treatment Outcomes

Program: Oral and Poster Abstracts
Session: 652. Multiple Myeloma and Plasma cell Dyscrasias: Clinical and Epidemiological: Poster II
Hematology Disease Topics & Pathways:
Adults, Workforce, Diversity, Equity, Inclusion, and Accessibility (DEI/DEIA) , Real World Evidence, Study Population
Sunday, December 12, 2021, 6:00 PM-8:00 PM

Laurent Garderet, MD, PhD1, Mohammad Al Hariri2*, Joanna Wasielica-Poslednik2*, Markus Munder3*, Kitti Kormányos4*, Camila Peña, MD5, Alessandro Gozzetti6*, Xiang Zhou7,8,9*, Anna Waszczuk-Gajda, MD10*, Laura Rosinol11*, Gabor Mikala, MD, PhD12*, Mateusz Krzystanski13*, Walter Lisch2*, David H. Vesole, MD, PhD14, Nora Szentmáry15* and Artur Jurczyszyn, MD16*

1Service Hematologie, Sorbonne Université, Hopital Pitié Salpêtière APHP, Paris, France
2Department of Ophthalmology, University Medical Center of the Johannes Gutenberg-University Mainz, Mainz, Germany, Mainz, Germany
3Department of Hematology, Medical Oncology, and Pneumology, University Medical Center of the Johannes Gutenberg University, Mainz, Germany
4Department of Ophthalmology, Semmelweis University, Budapest, Hungary, Budapest, Hungary
5Hematology Department, Hospital Del Salvador, Santiago, Chile
6Policlinico Le Scotte University of Siena, Siena, Italy
7Department of Internal Medicine II, Division of Oncology and Hematology, University Hospital Wuerzburg, WüRzburg, Germany
8Department of Internal Medicine II, Hematology and Oncology, University Hospital of Würzburg, Wurzburg, Germany
9Department of Internal Medicine II, Division of Oncology and Hematology, Würzburg University Hospital, Würzburg, Germany
10Department of Hematology, Oncology and Internal Medicine, Medical University of Warsaw, Warsaw, Poland
11Amyloidosis and Myeloma Unit. Department of Hematology. Hospital Clínic de Barcelona. IDIBAPS., Barcelona, Spain
12Department of Hematology and Stem Cell Transplantation, South Pest Central Hospital, Budapest, Hungary
13Plasma Cell Dyscrasia Center, Department of Hematology, Jagiellonian University Medical College, Krakow, Poland, Krakow, Philippines
14John Theurer Cancer Center, Hackensack University Medical Center, Hackensack, NJ
15Department of Ophthalmology, Semmelweis University, Budapest, Hungary 13 Dr. Rolf M. Schwiete Center for Limbal Stem Cell and Aniridia Research, Homburg/Saar,, Budapest, Hungary
16Department of Hematology, Jagiellonian University Medical College, Cracow, Poland


Monoclonal gammopathy of ocular significance (MGOS) is a rare subset of monoclonal gammopathy of clinical significance (MGCS) occurring secondary to plasma cell dyscrasia resulting in ocular manifestations. Given the rarity of these conditions, optimal management strategies are not defined; the approach is dependent upon the underlying cause of the monoclonal gammopathy and whether or not the patient’s vision is affected. We report our review of 23 cases with MGOS, more specifically on paraproteinemic keratopathy (PPK) the most common form, to obtain a better understanding of the patient characteristics, diagnosis and treatments.


We report an international retrospective series of patients with MGOS. Data was collected on patients with MGOS:there were no other inclusion criteria besides monoclonal gammopathy with an ophthalmologic manifestation; however, this report focuses only on patients with PPK. Efficacy outcomes were the hematologic and the ocular responses in patients with PPK. Hematologic responses were reported according to the IMWG response criteria. The ophthalmologic response to treatment was assessed by each contributing physician and reported as either complete, partial or no sight recovery.


We identified 23 patients with PPK in the setting of monoclonal gammopathy of unknown significance (MGUS), smoldering multiple myeloma (SMM), or multiple myeloma (MM) diagnosed between 2006 and 2019 in 7 countries. Table 1 summarizes the patients' characteristics. The ocular diagnosis was typically made at the same time or after the hematologic diagnosis. Eleven of 23 patients presented decreased vision. Four were treated by penetrating keratoplasty with or without systemic therapy, including chemotherapy with new generation anti-MM agents with or without autologous stem cell transplantation (ASCT). All patients with MM and 40% of those with other diagnoses such as SMM or MGUS received systemic therapy. In most cases, neither ocular nor hematologic treatment, even when ASCT was performed, afforded a durable improvement in the visual acuity despite initial responses. MGOS typically relapsed within one year of the initial response (Table 2).


To date, this is the largest retrospective study focusing on MGOS patients with monoclonal immunoglobulin deposits accumulating in the cornea and resulting in visual impairment. Further studies will be required to determine the optimal strategy to treat and prevent the relapse of ocular symptoms in patients with PPK and specifically to address the timing of keratoplasty and systemic chemotherapy and the role of maintenance therapy. Patients with corneal manifestation of unknown origin should undergo a hematologic check-up and patients with paraproteinemia should have a periodic ocular health assessment.

Disclosures: Garderet: Takeda: Consultancy; Sanofi: Consultancy; Amgen: Consultancy; Janssen: Consultancy; Celgene: Consultancy. Munder: Janssen: Consultancy, Honoraria; BMS: Consultancy, Honoraria; Abbvie: Consultancy; Takeda: Consultancy, Honoraria; Amgen: Honoraria; Sanofi: Consultancy; GSK: Consultancy; Incyte: Research Funding. Gozzetti: AbbVie: Honoraria; Janssen: Honoraria. Rosinol: Janssen, Celgene, Amgen and Takeda: Honoraria. Jurczyszyn: Janssen-Cilag, Amgen: Honoraria, Speakers Bureau.

Previous Abstract | Next Abstract >>
*signifies non-member of ASH